KA_Logo_CMYK_Fund Advisors_Primary.png
Kayne Anderson Energy Infrastructure Fund Provides Unaudited Balance Sheet Information and Announces Its Net Asset Value and Asset Coverage Ratios at August 31, 2024
September 04, 2024 19:10 ET | Kayne Anderson Energy Infrastructure Fund, Inc.
HOUSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Kayne Anderson Energy Infrastructure Fund, Inc. (the “Company”) (NYSE: KYN) today provided a summary unaudited statement of assets and liabilities and...
Logo-EN-TCEBlue.png
TC Energy reports strong second quarter 2024 operating and financial results
August 01, 2024 06:30 ET | TC Energy Corporation
CALGARY, Alberta, Aug. 01, 2024 (GLOBE NEWSWIRE) -- TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) released its second quarter results today. François Poirier, TC Energy’s...
barinthuslogo.jpg
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
June 12, 2024 16:01 ET | Barinthus Biotherapeutics
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Acri Capital Acquisition Corporation Announces Extension of the Deadline for an Initial Business Combination
June 12, 2024 16:00 ET | Acri Capital Acquisition Corporation
Austin, Texas, June 12, 2024 (GLOBE NEWSWIRE) -- Acri Capital Acquisition Corporation (the “Company”) (Nasdaq: ACAC), a special purpose acquisition company, today announced that, in order to extend...
Azuria_WS_RGB_pos (1).png
Azuria Announces Acquisition of Infrastructure Services Group LLC and Subsidiaries
June 11, 2024 10:36 ET | Azuria Water Solutions
Azuria Announces Acquisition of Infrastructure Services Group LLC and Subsidiaries
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim
June 03, 2024 08:14 ET | AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June 3, 2024 AUROBAC THERAPEUTICS, a...
Mural_Logo.jpg
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
May 23, 2024 17:00 ET | Mural Oncology, Inc.
ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3...
Mural_Logo.jpg
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 07:00 ET | Mural Oncology, Inc.
Mural Oncology reiterates cash runway projection into 4Q 2025, with sufficient capital to fund key clinical readouts.
Azuria_WS_RGB_pos (1).png
Aegion Rebrands as Azuria Water Solutions, Signaling a New Era in Water Infrastructure Solutions
April 25, 2024 13:58 ET | Azuria Water Solutions
Aegion Corporation today announced its official rebrand to Azuria Water Solutions, the leading provider of technology-enabled products and services.
boehringer_biopharmaceutical production_Biberach resized
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
April 16, 2024 04:35 ET | Boehringer Ingelheim
Human Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCE® and OFEV®Animal Health sales up 6.9 %* to EUR 4.7 bn, fueled by new product launchesR&D expenditures increase by 14.2% to EUR 5.8...